foscarnet has been researched along with Retinitis in 102 studies
Foscarnet: An antiviral agent used in the treatment of cytomegalovirus retinitis. Foscarnet also shows activity against human herpesviruses and HIV.
phosphonoformic acid : Phosphoric acid in which one of the hydroxy groups is replaced by a carboxylic acid group. It is used as the trisodium salt as an antiviral agent in the treatment of cytomegalovirus retinitis (CMV retinitis, an inflamation of the retina that can lead to blindness) and as an alternative to ganciclovir for AIDS patients who require concurrent antiretroviral therapy but are unable to tolerate ganciclovir due to haematological toxicity.
Retinitis: Inflammation of the RETINA. It is rarely limited to the retina, but is commonly associated with diseases of the choroid (CHORIORETINITIS) and of the OPTIC DISK (neuroretinitis).
| Excerpt | Relevance | Reference |
|---|---|---|
| "A cohort of 24 patients with acquired immunodeficiency syndrome (AIDS) and CMV retinitis received sodium phosphonoformate (foscarnet) as part of a controlled efficacy trial at the National Institutes of Health." | 10.17 | Increased survival of a cohort of patients with acquired immunodeficiency syndrome and cytomegalovirus retinitis who received sodium phosphonoformate (foscarnet). ( Baird, BF; Davey, RT; deSmet, MD; Falloon, J; Kovacs, JA; Masur, H; Mellow, S; Nussenblatt, RB; Palestine, AG; Polis, MA, 1993) |
| "Eleven clinical centers, a data coordinating center, and a fundus photograph reading center participated in a randomized, controlled, multicenter clinical trial comparing foscarnet and ganciclovir as primary therapy for previously untreated CMV retinitis in 240 patients with AIDS." | 9.08 | Foscarnet-Ganciclovir Cytomegalovirus Retinitis Trial: 5. Clinical features of cytomegalovirus retinitis at diagnosis. Studies of ocular complications of AIDS Research Group in collaboration with the AIDS Clinical Trials Group. ( , 1997) |
| "AIDS patients with newly diagnosed cytomegalovirus (CMV) retinitis who had just completed a 14-day course of ganciclovir induction therapy were randomly assigned to an alternating or concurrent combination regimen of chronic ganciclovir-foscarnet therapy for CMV retinitis." | 9.07 | Randomized phase I trial of two different combination foscarnet and ganciclovir chronic maintenance therapy regimens for AIDS patients with cytomegalovirus retinitis: AIDS clinical Trials Group Protocol 151. ( Bassiakos, Y; Geheb, H; Hooton, T; Jacobson, MA; Korvick, JA; Kramer, F; O'Donnell, JJ; Polsky, B; van der Horst, C; Walker, JD, 1994) |
| "Thirty-two patients with AIDS and previously untreated cytomegalovirus retinitis completed an induction course of foscarnet, 60 mg/kg every 8 h for 14 days, had retinitis stabilize, and were then randomly assigned to receive foscarnet maintenance as either a 90- or 120-mg/kg/day infusion administered over 2 h." | 9.07 | A dose-ranging study of daily maintenance intravenous foscarnet therapy for cytomegalovirus retinitis in AIDS. ( Causey, D; Chown, M; Davis, R; Hardy, D; Heinemann, MH; Holland, GN; Jacobson, MA; Kuppermann, BD; O'Donnell, JJ; Polsky, B, 1993) |
| "The administration of foscarnet decreases the rate of progression of cytomegalovirus retinitis in persons with AIDS." | 9.07 | A randomized, controlled trial of foscarnet in the treatment of cytomegalovirus retinitis in patients with AIDS. ( Baird, BF; Davey, RT; Davis, M; De Smet, MD; Falloon, J; Kovacs, JA; Palestine, AG; Polis, MA; Zunich, KM; Zurlo, JJ, 1991) |
| "Ganciclovir and Foscarnet were compared in an open randomised trial as treatment and secondary prophylaxis of cytomegalovirus (CMV) retinitis in patients with AIDS." | 9.07 | Foscarnet and Ganciclovir in the treatment of CMV retinitis in AIDS patients: a randomised comparison. ( Gazzard, BG; Harman, C; Mathalone, B; Mitchell, S; Moyle, G, 1992) |
| "In a controlled trial of foscarnet in the treatment of cytomegalovirus (CMV) retinitis in patients with the acquired immunodeficiency syndrome (AIDS), patients with non-immediately sight-threatening lesions were randomized to receive immediate treatment with foscarnet or foscarnet treatment delayed until the first signs of retinitis progression." | 9.07 | Design of a randomized controlled trial of foscarnet in patients with cytomegalovirus retinitis associated with acquired immunodeficiency syndrome. ( Polis, MA, 1992) |
| "These results suggest that for patients with AIDS, and cytomegalovirus retinitis, treatment with foscarnet offers a survival advantage over treatment with ganciclovir, although the patients may not tolerate foscarnet as well as ganciclovir." | 9.07 | Mortality in patients with the acquired immunodeficiency syndrome treated with either foscarnet or ganciclovir for cytomegalovirus retinitis. ( , 1992) |
| "Circulating human immunodeficiency virus (HIV) p24 antigen levels were measured in 22 AIDS patients who had detectable serum antigen at baseline after induction and maintenance therapy of foscarnet for cytomegalovirus retinitis in phase I/II multicenter trials." | 9.07 | Effect of foscarnet therapy on human immunodeficiency virus p24 antigen levels in AIDS patients with cytomegalovirus retinitis. ( Causey, DM; Davis, RB; Grieco, MH; Hooton, TM; Jacobson, MA; McKinley, GF; Parenti, DM; Reddy, MM; van der Horst, CM, 1992) |
| "Induction regimens of foscarnet and ganciclovir are highly effective in arresting cytomegalovirus (CMV) retinitis in patients with AIDS." | 8.78 | Foscarnet and ganciclovir in the treatment of cytomegalovirus retinitis. ( Polis, MA, 1992) |
| "The pyrophosphate analogue, foscarnet, selectively inhibits the DNA polymerase of human herpes viruses, including cytomegalovirus, and the reverse transcriptase of HIV." | 8.78 | Foscarnet. A review of its antiviral activity, pharmacokinetic properties and therapeutic use in immunocompromised patients with cytomegalovirus retinitis. ( Chrisp, P; Clissold, SP, 1991) |
| "The use of ganciclovir in the treatment of cytomegalovirus (CMV) retinitis in patients with acquired immunodeficiency syndrome (AIDS) is limited by marrow toxicity and by the development of resistance to this agent in CMV strains capable of causing progressive disease." | 8.78 | Maintenance therapy for cytomegalovirus retinitis in patients with acquired immunodeficiency syndrome: foscarnet. ( Jacobson, MA, 1992) |
| "To report the use of intravenous (IV) antiviral agents and intravitreal ganciclovir injections in three immunocompetent patients with severe acute retinal necrosis (ARN)." | 7.72 | Successful treatment with combination of systemic antiviral drugs and intravitreal ganciclovir injections in the management of severe necrotizing herpetic retinitis. ( Bodaghi, B; Cassoux, N; Chau Tran, TH; Lehoang, P, 2003) |
| "The efficacy of intravitreal foscarnet injections was evaluated in a rabbit model of Herpes simplex virus type-1 (HSV-1) retinitis." | 7.70 | Reducing chorioretinal viral counts with intravitreal foscarnet injections in a rabbit model of Herpes simplex virus type-1 retinitis. ( Beauchamp, D; Bergeron, MG; Delorme, C; Désormeaux, A; Gourde, P; Morin, NJ; Omar, RF; Rousseau, A; Tremblay, MJ, 1999) |
| "Foscarnet is an investigational antiviral agent that has been used effectively in the treatment of cytomegalovirus (CMV) retinitis in AIDS patients." | 7.68 | Successful foscarnet therapy for cytomegalovirus retinitis in an AIDS patient undergoing hemodialysis: rationale for empiric dosing and plasma level monitoring. ( Gambertoglio, JG; Graziani, AL; Grunwald, JE; MacGregor, RR; Weiss, R, 1991) |
| "Infections caused by cytomegalovirus (CMV) resistant in vitro to ganciclovir, defined as requiring greater than 6 mumols of ganciclovir for ED50 have developed in some AIDS patients with progressive CMV retinitis despite chronic ganciclovir therapy." | 7.68 | Foscarnet therapy for ganciclovir-resistant cytomegalovirus retinitis in patients with AIDS. ( Drew, WL; Feinberg, J; Jacobson, MA; Miner, RD; O'Donnell, JJ; Parenti, D; Whitmore, PV, 1991) |
| "Ganciclovir and foscarnet are both effective for cytomegalovirus retinitis in patients with acquired immunodeficiency syndrome, but the benefits of either agent given alone are limited." | 7.68 | Treatment of aggressive cytomegalovirus retinitis with ganciclovir in combination with foscarnet in a child infected with human immunodeficiency virus. ( Butler, KM; De Smet, MD; Husson, RN; Jarosinski, P; Lovato, G; Manjunath, K; Montrella, K; Mueller, B; Nussenblatt, RB; Pizzo, PA, 1992) |
| " Following allogeneic bone marrow transplantation, he developed cytomegalovirus retinitis, which was treated successfully with trisodium phosphonoformate (foscarnet)." | 7.67 | Foscarnet as treatment for cytomegalovirus retinitis following bone marrow transplantation. ( Arthur, C; Ganly, PS; Goldman, JM; Schulenburg, WE, 1988) |
| "Ten patients with acquired immunodeficiency syndrome with newly diagnosed cytomegalovirus (CMV) retinitis were treated with an induction regimen of intravenous foscarnet, 60 mg/kg of body weight, administered as a 2-h infusion and repeated every 8 h for 14 days." | 7.67 | Foscarnet treatment of cytomegalovirus retinitis in patients with the acquired immunodeficiency syndrome. ( Jacobson, MA; Mills, J; O'Donnell, JJ, 1989) |
| "Patients were randomized to one of three therapeutic regimens: induction with foscarnet sodium at 90 mg/kg intravenously every 12 hours for 2 weeks, followed by maintenance at a dosage of 120 mg/kg per day (foscarnet group); induction with ganciclovir sodium at 5 mg/kg intravenously every 12 hours for 2 weeks followed by maintenance at 10 mg/kg per day (ganciclovir group); or continuation of previous maintenance therapy plus induction with the other drug (either ganciclovir or foscarnet) for 2 weeks followed by maintenance therapy with both drugs, ganciclovir sodium at 5 mg/kg per day and foscarnet sodium at 90 mg/kg per day (combination therapy group)." | 6.68 | Combination foscarnet and ganciclovir therapy vs monotherapy for the treatment of relapsed cytomegalovirus retinitis in patients with AIDS. The Cytomegalovirus Retreatment Trial. The Studies of Ocular Complications of AIDS Research Group in Collaboration ( , 1996) |
| "Foscarnet has a low solubility and a high degree of ionization at physiologic pH, requiring it to be administered in higher doses and larger volumes." | 6.38 | Approaches to the treatment of cytomegalovirus retinitis: ganciclovir and foscarnet. ( Jacobson, MA; O'Donnell, JJ, 1991) |
| "A cohort of 24 patients with acquired immunodeficiency syndrome (AIDS) and CMV retinitis received sodium phosphonoformate (foscarnet) as part of a controlled efficacy trial at the National Institutes of Health." | 6.17 | Increased survival of a cohort of patients with acquired immunodeficiency syndrome and cytomegalovirus retinitis who received sodium phosphonoformate (foscarnet). ( Baird, BF; Davey, RT; deSmet, MD; Falloon, J; Kovacs, JA; Masur, H; Mellow, S; Nussenblatt, RB; Palestine, AG; Polis, MA, 1993) |
| "After withdrawal from maintenance treatment, a relapse of cytomegalovirus retinitis occurred, which was again successfully treated with ganciclovir." | 5.28 | 2.5 years survival with sequential ganciclovir/foscarnet treatment in a patient with acquired immune deficiency syndrome and cytomegalovirus retinitis. ( Geier, SA; Goebel, FD; Klauss, V; Kronawitter, U; Matuschke, A, 1992) |
| "Eight patients with acquired immunodeficiency syndrome and serious CMV retinitis received 2-h intravenous infusions of foscarnet at a dosage of 60 mg/kg of body weight every 8 h for 14 days." | 5.28 | Pharmacokinetics of intermittently administered intravenous foscarnet in the treatment of acquired immunodeficiency syndrome patients with serious cytomegalovirus retinitis. ( Aweeka, F; Gambertoglio, J; Jacobson, MA; Mills, J, 1989) |
| "We treated a patient who had acquired immunodeficiency syndrome and cytomegalovirus retinitis of the left eye." | 5.28 | Intravitreal foscarnet for cytomegalovirus retinitis in a patient with acquired immunodeficiency syndrome. ( Chipont, E; Díaz-Llopis, M; España, E; Menezo, JL; Navea, A; Sanchez, S, 1992) |
| "Foscarnet was discontinued because of adverse events in 3 (3%) of 97 patients, with treatment being stopped in 2 patients because of renal insufficiency and in 1 patient because of an acute neurologic disorder." | 5.28 | Foscarnet induction therapy for cytomegalovirus retinitis in AIDS: comparison of twice-daily and three-times-daily regimens. ( Brancon, C; Caumes, E; Cochereau-Massin, I; Dahan, R; Dohin, E; Gentilini, M; Katlama, C; Robinet, M; Rogeaux, O, 1992) |
| "Eleven clinical centers, a data coordinating center, and a fundus photograph reading center participated in a randomized, controlled, multicenter clinical trial comparing foscarnet and ganciclovir as primary therapy for previously untreated CMV retinitis in 240 patients with AIDS." | 5.08 | Foscarnet-Ganciclovir Cytomegalovirus Retinitis Trial: 5. Clinical features of cytomegalovirus retinitis at diagnosis. Studies of ocular complications of AIDS Research Group in collaboration with the AIDS Clinical Trials Group. ( , 1997) |
| "The administration of foscarnet decreases the rate of progression of cytomegalovirus retinitis in persons with AIDS." | 5.07 | A randomized, controlled trial of foscarnet in the treatment of cytomegalovirus retinitis in patients with AIDS. ( Baird, BF; Davey, RT; Davis, M; De Smet, MD; Falloon, J; Kovacs, JA; Palestine, AG; Polis, MA; Zunich, KM; Zurlo, JJ, 1991) |
| "AIDS patients with newly diagnosed cytomegalovirus (CMV) retinitis who had just completed a 14-day course of ganciclovir induction therapy were randomly assigned to an alternating or concurrent combination regimen of chronic ganciclovir-foscarnet therapy for CMV retinitis." | 5.07 | Randomized phase I trial of two different combination foscarnet and ganciclovir chronic maintenance therapy regimens for AIDS patients with cytomegalovirus retinitis: AIDS clinical Trials Group Protocol 151. ( Bassiakos, Y; Geheb, H; Hooton, T; Jacobson, MA; Korvick, JA; Kramer, F; O'Donnell, JJ; Polsky, B; van der Horst, C; Walker, JD, 1994) |
| "Thirty-two patients with AIDS and previously untreated cytomegalovirus retinitis completed an induction course of foscarnet, 60 mg/kg every 8 h for 14 days, had retinitis stabilize, and were then randomly assigned to receive foscarnet maintenance as either a 90- or 120-mg/kg/day infusion administered over 2 h." | 5.07 | A dose-ranging study of daily maintenance intravenous foscarnet therapy for cytomegalovirus retinitis in AIDS. ( Causey, D; Chown, M; Davis, R; Hardy, D; Heinemann, MH; Holland, GN; Jacobson, MA; Kuppermann, BD; O'Donnell, JJ; Polsky, B, 1993) |
| "In a controlled trial of foscarnet in the treatment of cytomegalovirus (CMV) retinitis in patients with the acquired immunodeficiency syndrome (AIDS), patients with non-immediately sight-threatening lesions were randomized to receive immediate treatment with foscarnet or foscarnet treatment delayed until the first signs of retinitis progression." | 5.07 | Design of a randomized controlled trial of foscarnet in patients with cytomegalovirus retinitis associated with acquired immunodeficiency syndrome. ( Polis, MA, 1992) |
| "Ganciclovir and Foscarnet were compared in an open randomised trial as treatment and secondary prophylaxis of cytomegalovirus (CMV) retinitis in patients with AIDS." | 5.07 | Foscarnet and Ganciclovir in the treatment of CMV retinitis in AIDS patients: a randomised comparison. ( Gazzard, BG; Harman, C; Mathalone, B; Mitchell, S; Moyle, G, 1992) |
| "Circulating human immunodeficiency virus (HIV) p24 antigen levels were measured in 22 AIDS patients who had detectable serum antigen at baseline after induction and maintenance therapy of foscarnet for cytomegalovirus retinitis in phase I/II multicenter trials." | 5.07 | Effect of foscarnet therapy on human immunodeficiency virus p24 antigen levels in AIDS patients with cytomegalovirus retinitis. ( Causey, DM; Davis, RB; Grieco, MH; Hooton, TM; Jacobson, MA; McKinley, GF; Parenti, DM; Reddy, MM; van der Horst, CM, 1992) |
| "These results suggest that for patients with AIDS, and cytomegalovirus retinitis, treatment with foscarnet offers a survival advantage over treatment with ganciclovir, although the patients may not tolerate foscarnet as well as ganciclovir." | 5.07 | Mortality in patients with the acquired immunodeficiency syndrome treated with either foscarnet or ganciclovir for cytomegalovirus retinitis. ( , 1992) |
| "Induction regimens of foscarnet and ganciclovir are highly effective in arresting cytomegalovirus (CMV) retinitis in patients with AIDS." | 4.78 | Foscarnet and ganciclovir in the treatment of cytomegalovirus retinitis. ( Polis, MA, 1992) |
| "The use of ganciclovir in the treatment of cytomegalovirus (CMV) retinitis in patients with acquired immunodeficiency syndrome (AIDS) is limited by marrow toxicity and by the development of resistance to this agent in CMV strains capable of causing progressive disease." | 4.78 | Maintenance therapy for cytomegalovirus retinitis in patients with acquired immunodeficiency syndrome: foscarnet. ( Jacobson, MA, 1992) |
| " The antiviral agents ganciclovir and foscarnet are effective against CMV retinitis and gastrointestinal diseases, although dose-limiting adverse effects and the need for long-term maintenance therapy may hinder their use in many patients." | 4.78 | Treatment and prophylaxis of cytomegalovirus disease. ( Jacobson, PA; Levinson, ML, 1992) |
| "The pyrophosphate analogue, foscarnet, selectively inhibits the DNA polymerase of human herpes viruses, including cytomegalovirus, and the reverse transcriptase of HIV." | 4.78 | Foscarnet. A review of its antiviral activity, pharmacokinetic properties and therapeutic use in immunocompromised patients with cytomegalovirus retinitis. ( Chrisp, P; Clissold, SP, 1991) |
| "To report the use of intravenous (IV) antiviral agents and intravitreal ganciclovir injections in three immunocompetent patients with severe acute retinal necrosis (ARN)." | 3.72 | Successful treatment with combination of systemic antiviral drugs and intravitreal ganciclovir injections in the management of severe necrotizing herpetic retinitis. ( Bodaghi, B; Cassoux, N; Chau Tran, TH; Lehoang, P, 2003) |
| "The efficacy of intravitreal foscarnet injections was evaluated in a rabbit model of Herpes simplex virus type-1 (HSV-1) retinitis." | 3.70 | Reducing chorioretinal viral counts with intravitreal foscarnet injections in a rabbit model of Herpes simplex virus type-1 retinitis. ( Beauchamp, D; Bergeron, MG; Delorme, C; Désormeaux, A; Gourde, P; Morin, NJ; Omar, RF; Rousseau, A; Tremblay, MJ, 1999) |
| "An AIDS patient experienced an exacerbation of cytomegalovirus retinitis and was treated with foscarnet." | 3.68 | Foscarnet-induced severe hypomagnesemia and other electrolyte disorders. ( Gearhart, MO; Sorg, TB, 1993) |
| "Sequential visual field testing is an extremely helpful adjunct to ophthalmoscopy and fundus photography in the management of cytomegalovirus (CMV) retinitis with the antiviral agents ganciclovir or foscarnet in patients with the acquired immune deficiency syndrome (AIDS)." | 3.68 | Visual field testing in the management of cytomegalovirus retinitis. ( Bachman, DM; Bruni, LM; DiGioia, RA; Harris, PJ; McMackin, CM; Pistole, MC; Thomas, RM; Ward, DJ, 1992) |
| "Foscarnet and ganciclovir appear to be of similar effectiveness in halting active infection when given as induction therapy and in forestalling progression of disease when given as maintenance therapy in persons with AIDS who have cytomegalovirus (CMV) retinitis." | 3.68 | Therapeutic algorithm for treatment of cytomegalovirus retinitis in persons with AIDS. A roundtable summary. ( Balfour, HH; Drew, WL; Hardy, WD; Heinemann, MH; Polsky, B, 1992) |
| "Ganciclovir and foscarnet are both effective for cytomegalovirus retinitis in patients with acquired immunodeficiency syndrome, but the benefits of either agent given alone are limited." | 3.68 | Treatment of aggressive cytomegalovirus retinitis with ganciclovir in combination with foscarnet in a child infected with human immunodeficiency virus. ( Butler, KM; De Smet, MD; Husson, RN; Jarosinski, P; Lovato, G; Manjunath, K; Montrella, K; Mueller, B; Nussenblatt, RB; Pizzo, PA, 1992) |
| "Infections caused by cytomegalovirus (CMV) resistant in vitro to ganciclovir, defined as requiring greater than 6 mumols of ganciclovir for ED50 have developed in some AIDS patients with progressive CMV retinitis despite chronic ganciclovir therapy." | 3.68 | Foscarnet therapy for ganciclovir-resistant cytomegalovirus retinitis in patients with AIDS. ( Drew, WL; Feinberg, J; Jacobson, MA; Miner, RD; O'Donnell, JJ; Parenti, D; Whitmore, PV, 1991) |
| "Foscarnet is an investigational antiviral agent that has been used effectively in the treatment of cytomegalovirus (CMV) retinitis in AIDS patients." | 3.68 | Successful foscarnet therapy for cytomegalovirus retinitis in an AIDS patient undergoing hemodialysis: rationale for empiric dosing and plasma level monitoring. ( Gambertoglio, JG; Graziani, AL; Grunwald, JE; MacGregor, RR; Weiss, R, 1991) |
| "Ten patients with acquired immunodeficiency syndrome with newly diagnosed cytomegalovirus (CMV) retinitis were treated with an induction regimen of intravenous foscarnet, 60 mg/kg of body weight, administered as a 2-h infusion and repeated every 8 h for 14 days." | 3.67 | Foscarnet treatment of cytomegalovirus retinitis in patients with the acquired immunodeficiency syndrome. ( Jacobson, MA; Mills, J; O'Donnell, JJ, 1989) |
| " Following allogeneic bone marrow transplantation, he developed cytomegalovirus retinitis, which was treated successfully with trisodium phosphonoformate (foscarnet)." | 3.67 | Foscarnet as treatment for cytomegalovirus retinitis following bone marrow transplantation. ( Arthur, C; Ganly, PS; Goldman, JM; Schulenburg, WE, 1988) |
| "Patients were randomized to one of three therapeutic regimens: induction with foscarnet sodium at 90 mg/kg intravenously every 12 hours for 2 weeks, followed by maintenance at a dosage of 120 mg/kg per day (foscarnet group); induction with ganciclovir sodium at 5 mg/kg intravenously every 12 hours for 2 weeks followed by maintenance at 10 mg/kg per day (ganciclovir group); or continuation of previous maintenance therapy plus induction with the other drug (either ganciclovir or foscarnet) for 2 weeks followed by maintenance therapy with both drugs, ganciclovir sodium at 5 mg/kg per day and foscarnet sodium at 90 mg/kg per day (combination therapy group)." | 2.68 | Combination foscarnet and ganciclovir therapy vs monotherapy for the treatment of relapsed cytomegalovirus retinitis in patients with AIDS. The Cytomegalovirus Retreatment Trial. The Studies of Ocular Complications of AIDS Research Group in Collaboration ( , 1996) |
| "Foscarnet has a low solubility and a high degree of ionization at physiologic pH, requiring it to be administered in higher doses and larger volumes." | 2.38 | Approaches to the treatment of cytomegalovirus retinitis: ganciclovir and foscarnet. ( Jacobson, MA; O'Donnell, JJ, 1991) |
| " Myelosuppression may be further exacerbated in AIDS patients by such other agents as zidovudine or trimethoprim/sulfamethoxazole, often necessitating dosage reductions or discontinuation of these agents in patients receiving ganciclovir." | 2.38 | Foscarnet sodium. ( Baltz, JK; Minor, JR, 1991) |
| "CMV disease is a major problem in AIDS, though with a different profile from that seen in other immunosuppressed patients." | 2.38 | Cytomegalovirus infection in the acquired immune deficiency syndrome. ( Pinching, AJ, 1989) |
| " An important direction for future clinical research is the development of more effective and less toxic therapy, as well as orally bioavailable drugs for maintenance therapy." | 2.37 | Serious cytomegalovirus disease in the acquired immunodeficiency syndrome (AIDS). Clinical findings, diagnosis, and treatment. ( Jacobson, MA; Mills, J, 1988) |
| "Cytomegalovirus retinitis is probably the result of hematogenous spread of the virus to the retina after systemic reactivation of a latent cytomegalovirus infection." | 2.37 | The diagnosis of cytomegalovirus retinitis. ( Bloom, JN; Palestine, AG, 1988) |
| "However, she developed optic-nerve papillitis, and central retinal vein occlusion related to the severe swelling of the optic-nerve, and began steroid pulse therapy." | 1.62 | Effects of intraocular treatments for Epstein-Barr virus (EBV) retinitis: A case report. ( Komoto, T; Mushiga, Y; Nagai, N; Ozawa, Y, 2021) |
| "Retinitis was clinically graded by indirect ophthalmoscopy, and the retinitis scores were compared across the treatment and control groups." | 1.30 | Treatment of herpes retinitis in an animal model with a sustained delivery antiviral drug, liposomal 1-O-octadecyl-SN-glycerol-3-phosphonoformate. ( Bergeron-Lynn, G; Chaidhawangul, S; Cheng, L; Freeman, WR; Gardner, MF; Hostetler, KY; Mach-Hofacre, B; Mueller, AJ; Ozerdem, U; Severson, GM, 1999) |
| "The initial and maintenance treatment of CMV retinitis must be individualized based on the characteristics of the lesions, including location and extent, specific patient factors, and characteristics of available therapies among others." | 1.30 | Guidelines for the treatment of cytomegalovirus diseases in patients with AIDS in the era of potent antiretroviral therapy: recommendations of an international panel. International AIDS Society-USA. ( Benson, CA; Deutsch, TA; Dieterich, DT; Drew, WL; Feinberg, J; Friedberg, DN; Griffiths, PD; Hardy, WD; Holland, GN; Jabs, DA; Jacobson, MA; Kessler, HA; Polis, MA; Powderly, WG; Spector, SA; Walmsley, S; Whitley, RJ, 1998) |
| "Cytomegalovirus retinitis is the most frequent ocular opportunistic infection in AIDS patients." | 1.29 | Intravitreal use of foscarnet: retinotoxicity of repeated injections in the rabbit eye. ( De Caro, G; Secchi, AG; Tognon, MS; Turrini, B, 1994) |
| "We treated a patient who had acquired immunodeficiency syndrome and cytomegalovirus retinitis of the left eye." | 1.28 | Intravitreal foscarnet for cytomegalovirus retinitis in a patient with acquired immunodeficiency syndrome. ( Chipont, E; Díaz-Llopis, M; España, E; Menezo, JL; Navea, A; Sanchez, S, 1992) |
| "After withdrawal from maintenance treatment, a relapse of cytomegalovirus retinitis occurred, which was again successfully treated with ganciclovir." | 1.28 | 2.5 years survival with sequential ganciclovir/foscarnet treatment in a patient with acquired immune deficiency syndrome and cytomegalovirus retinitis. ( Geier, SA; Goebel, FD; Klauss, V; Kronawitter, U; Matuschke, A, 1992) |
| "Recurrences were treated with high-dose reinduction therapy with good or partial response in more than 80% of cases." | 1.28 | [Cytomegalovirus retinitis in AIDS. Effectiveness and complications of long-term therapy]. ( Fabricius, EM; Popescu, M; Schmitz, K, 1992) |
| "Foscarnet was discontinued because of adverse events in 3 (3%) of 97 patients, with treatment being stopped in 2 patients because of renal insufficiency and in 1 patient because of an acute neurologic disorder." | 1.28 | Foscarnet induction therapy for cytomegalovirus retinitis in AIDS: comparison of twice-daily and three-times-daily regimens. ( Brancon, C; Caumes, E; Cochereau-Massin, I; Dahan, R; Dohin, E; Gentilini, M; Katlama, C; Robinet, M; Rogeaux, O, 1992) |
| "Fifty AIDS patients were investigated for human cytomegalovirus (HCMV) viraemia when potentially HCMV-related clinical symptoms or syndromes were observed." | 1.28 | Early virus isolation, early structural antigen detection and DNA amplification by the polymerase chain reaction in polymorphonuclear leukocytes from AIDS patients with human cytomegalovirus viraemia. ( Gaballo, A; Gerna, G; Milanesi, G; Parea, M; Percivalle, E; Zavattoni, M; Zipeto, D, 1991) |
| "Eight patients with acquired immunodeficiency syndrome and serious CMV retinitis received 2-h intravenous infusions of foscarnet at a dosage of 60 mg/kg of body weight every 8 h for 14 days." | 1.28 | Pharmacokinetics of intermittently administered intravenous foscarnet in the treatment of acquired immunodeficiency syndrome patients with serious cytomegalovirus retinitis. ( Aweeka, F; Gambertoglio, J; Jacobson, MA; Mills, J, 1989) |
| "Neutropenia was the most frequent and serious side-effect of ganciclovir, 76% patients having neutrophil counts less than 1." | 1.28 | Cytomegalovirus infection in AIDS. Patterns of disease, response to therapy and trends in survival. ( Anderson, S; Beck, EJ; Coker, R; Coleman, D; Harris, JR; Main, J; Migdal, C; Peters, BS; Pinching, AJ, 1991) |
| " Maintenance therapy with DHPG would appear to be necessary to prevent relapse, but the logistics of this are difficult, and the effective dosage of DHPG is as yet uncertain." | 1.27 | Treatment of CMV retinitis in an AIDS patient. ( Acheson, JF; Bradbeer, C; Shah, SM; Spalton, DJ; Thin, RN, 1987) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 14 (13.73) | 18.7374 |
| 1990's | 83 (81.37) | 18.2507 |
| 2000's | 3 (2.94) | 29.6817 |
| 2010's | 1 (0.98) | 24.3611 |
| 2020's | 1 (0.98) | 2.80 |
| Authors | Studies |
|---|---|
| Mushiga, Y | 1 |
| Komoto, T | 1 |
| Nagai, N | 1 |
| Ozawa, Y | 1 |
| Xu, K | 1 |
| Chin, EK | 1 |
| Mahajan, VB | 1 |
| Almeida, DR | 1 |
| Hubacek, P | 1 |
| Keslova, P | 1 |
| Formankova, R | 1 |
| Pochop, P | 1 |
| Cinek, O | 1 |
| Zajac, M | 1 |
| Lochmanova, J | 1 |
| Stary, J | 1 |
| Sedlacek, P | 1 |
| Zambarakji, HJ | 1 |
| Obi, AA | 1 |
| Mitchell, SM | 1 |
| Chau Tran, TH | 1 |
| Cassoux, N | 1 |
| Bodaghi, B | 1 |
| Lehoang, P | 2 |
| Holland, GN | 3 |
| Levinson, RD | 1 |
| Jacobson, MA | 15 |
| Kramer, F | 1 |
| Bassiakos, Y | 1 |
| Hooton, T | 1 |
| Polsky, B | 3 |
| Geheb, H | 1 |
| O'Donnell, JJ | 6 |
| Walker, JD | 1 |
| Korvick, JA | 1 |
| van der Horst, C | 1 |
| Freeman, WR | 4 |
| Turrini, B | 1 |
| Tognon, MS | 1 |
| De Caro, G | 1 |
| Secchi, AG | 1 |
| Polis, MA | 5 |
| deSmet, MD | 1 |
| Baird, BF | 2 |
| Mellow, S | 1 |
| Falloon, J | 2 |
| Davey, RT | 2 |
| Kovacs, JA | 2 |
| Palestine, AG | 3 |
| Nussenblatt, RB | 2 |
| Masur, H | 2 |
| Moyle, G | 2 |
| Barton, S | 1 |
| Gazzard, BG | 3 |
| Gearhart, MO | 1 |
| Sorg, TB | 1 |
| Pearson, PA | 1 |
| Jaffe, GJ | 1 |
| Ashton, P | 1 |
| Keijer, WJ | 1 |
| Burger, DM | 1 |
| Neuteboom, GH | 1 |
| Vrooland, JL | 1 |
| Meenhorst, PL | 1 |
| Koks, CH | 1 |
| Beijnen, JH | 1 |
| Brockmeyer, NH | 1 |
| Hengge, UR | 1 |
| Mertins, L | 1 |
| Malessa, R | 1 |
| Steinmetz, R | 1 |
| Gooss, M | 1 |
| Flores-Aguilar, M | 1 |
| Kuppermann, BD | 2 |
| Quiceno, JI | 2 |
| Dankner, WM | 1 |
| Wolf, DG | 1 |
| Capparelli, EV | 1 |
| Connor, JD | 1 |
| Sherwood, CH | 1 |
| Fullerton, S | 1 |
| Gambertoglio, JG | 2 |
| Causey, D | 1 |
| Hardy, D | 1 |
| Chown, M | 1 |
| Davis, R | 1 |
| Heinemann, MH | 3 |
| Jabs, DA | 3 |
| Weinberg, DV | 2 |
| Lyon, AT | 1 |
| Cunningham, ET | 1 |
| Moorthy, RS | 1 |
| Teich, SA | 1 |
| Berger, BB | 1 |
| Minturn, JT | 1 |
| Kumar, S | 1 |
| Rao, NA | 2 |
| Fowell, SM | 1 |
| Loose, IA | 1 |
| Jampol, LM | 2 |
| Zaknun, D | 1 |
| Zangerle, R | 1 |
| Kapelari, K | 1 |
| Fischer, H | 1 |
| Sailer, M | 1 |
| McIntosh, K | 1 |
| Lalezari, JP | 1 |
| Lee, MS | 1 |
| Cooney, EL | 1 |
| Stoessel, KM | 1 |
| Gariano, RF | 1 |
| Whitley, RJ | 1 |
| Friedberg, DN | 1 |
| Dieterich, DT | 1 |
| Hardy, WD | 2 |
| Deutsch, TA | 1 |
| Feinberg, J | 2 |
| Spector, SA | 1 |
| Walmsley, S | 1 |
| Drew, WL | 3 |
| Powderly, WG | 1 |
| Griffiths, PD | 1 |
| Benson, CA | 1 |
| Kessler, HA | 1 |
| Cheng, L | 2 |
| Hostetler, KY | 2 |
| Chaidhawangul, S | 1 |
| Gardner, MF | 2 |
| Ozerdem, U | 1 |
| Bergeron-Lynn, G | 2 |
| Mach-Hofacre, B | 1 |
| Mueller, AJ | 1 |
| Severson, GM | 1 |
| Avila, CP | 1 |
| Keefe, KS | 2 |
| Beadle, JR | 1 |
| Wiley, CA | 2 |
| Morin, NJ | 1 |
| Delorme, C | 1 |
| Gourde, P | 1 |
| Omar, RF | 1 |
| Désormeaux, A | 1 |
| Tremblay, MJ | 1 |
| Beauchamp, D | 1 |
| Rousseau, A | 1 |
| Bergeron, MG | 1 |
| Healy, B | 1 |
| Hirsch, MS | 1 |
| Butler, KM | 1 |
| De Smet, MD | 2 |
| Husson, RN | 1 |
| Mueller, B | 1 |
| Manjunath, K | 1 |
| Montrella, K | 1 |
| Lovato, G | 1 |
| Jarosinski, P | 1 |
| Pizzo, PA | 1 |
| Salit, IE | 1 |
| Evans, JK | 1 |
| Scoular, A | 1 |
| Miller, RF | 2 |
| Wilson, RJ | 1 |
| Skolnik, PR | 1 |
| Deray, G | 1 |
| Katlama, C | 3 |
| Jacobs, C | 1 |
| Bachman, DM | 2 |
| Dohin, E | 1 |
| Caumes, E | 1 |
| Cochereau-Massin, I | 1 |
| Brancon, C | 1 |
| Robinet, M | 2 |
| Rogeaux, O | 1 |
| Dahan, R | 1 |
| Gentilini, M | 1 |
| Balfour, HH | 1 |
| Evans, LM | 1 |
| Grossman, ME | 1 |
| Cotte, L | 1 |
| Langlois, M | 1 |
| Trepo, C | 1 |
| Reddy, MM | 1 |
| Grieco, MH | 1 |
| McKinley, GF | 1 |
| Causey, DM | 1 |
| van der Horst, CM | 1 |
| Parenti, DM | 1 |
| Hooton, TM | 1 |
| Davis, RB | 1 |
| Levinson, ML | 1 |
| Jacobson, PA | 1 |
| Harman, C | 1 |
| Mitchell, S | 1 |
| Mathalone, B | 1 |
| Peterson, TJ | 1 |
| Crapotta, J | 1 |
| Listhaus, AD | 1 |
| Bruni, LM | 1 |
| DiGioia, RA | 1 |
| Harris, PJ | 1 |
| McMackin, CM | 1 |
| Pistole, MC | 1 |
| Thomas, RM | 1 |
| Ward, DJ | 1 |
| Díaz-Llopis, M | 1 |
| Chipont, E | 1 |
| Sanchez, S | 1 |
| España, E | 1 |
| Navea, A | 1 |
| Menezo, JL | 1 |
| Silvia, PA | 1 |
| Malin, A | 1 |
| Geier, SA | 1 |
| Klauss, V | 1 |
| Matuschke, A | 1 |
| Kronawitter, U | 1 |
| Goebel, FD | 1 |
| Morinelli, EN | 1 |
| Dugel, PU | 1 |
| Lee, M | 1 |
| Klatt, EC | 1 |
| Schmitz, K | 1 |
| Fabricius, EM | 1 |
| Popescu, M | 1 |
| Morris, DJ | 1 |
| Wood, CA | 1 |
| Whitmore, PV | 1 |
| Miner, RD | 1 |
| Parenti, D | 1 |
| MacGregor, RR | 1 |
| Graziani, AL | 1 |
| Weiss, R | 1 |
| Grunwald, JE | 1 |
| Zurlo, JJ | 1 |
| Zunich, KM | 1 |
| Davis, M | 1 |
| Marwick, C | 1 |
| Nightingale, SL | 1 |
| Peters, BS | 1 |
| Beck, EJ | 1 |
| Anderson, S | 1 |
| Coleman, D | 1 |
| Coker, R | 1 |
| Main, J | 1 |
| Migdal, C | 2 |
| Harris, JR | 2 |
| Pinching, AJ | 2 |
| Harb, GE | 1 |
| Bacchetti, P | 1 |
| Gerna, G | 1 |
| Zipeto, D | 1 |
| Parea, M | 1 |
| Percivalle, E | 1 |
| Zavattoni, M | 1 |
| Gaballo, A | 1 |
| Milanesi, G | 1 |
| Nelson, MR | 1 |
| Barter, G | 1 |
| Hawkins, D | 1 |
| Coker, RJ | 1 |
| Tomlinson, D | 1 |
| Horner, P | 1 |
| Chrisp, P | 1 |
| Clissold, SP | 1 |
| Paul, AA | 1 |
| Leeper, HF | 1 |
| Friberg, TR | 1 |
| Henderly, DE | 1 |
| Minor, JR | 1 |
| Baltz, JK | 1 |
| Fanning, MM | 2 |
| Read, SE | 2 |
| Benson, M | 1 |
| Vas, S | 1 |
| Rachlis, A | 2 |
| Kozousek, V | 1 |
| Mortimer, C | 1 |
| Harvey, P | 1 |
| Schwartz, C | 1 |
| Chew, E | 2 |
| Farese, RV | 1 |
| Schambelan, M | 1 |
| Hollander, H | 1 |
| Stringari, S | 1 |
| Girard, B | 1 |
| Marcel, P | 1 |
| Zazoun, L | 1 |
| Matheron, S | 1 |
| Rozenbaum, W | 1 |
| Morer, I | 1 |
| Lernestedt, JO | 1 |
| Mills, J | 4 |
| Aweeka, F | 2 |
| Gambertoglio, J | 2 |
| Wood, G | 1 |
| Whitby, M | 1 |
| Hogan, P | 1 |
| Frazer, I | 1 |
| Acheson, JF | 1 |
| Shah, SM | 1 |
| Spalton, DJ | 1 |
| Bradbeer, C | 1 |
| Thin, RN | 1 |
| Walmsley, SL | 1 |
| Vellend, H | 1 |
| Salit, I | 1 |
| Crowe, S | 1 |
| Levy, J | 1 |
| McManus, N | 1 |
| Bloom, JN | 1 |
| Ganly, PS | 1 |
| Arthur, C | 1 |
| Goldman, JM | 1 |
| Schulenburg, WE | 2 |
| Heley, A | 1 |
| Singer, DR | 1 |
| Fallon, TJ | 1 |
| Williams, G | 1 |
| Cohen, J | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Phase I Open-Labeled Study of Long Term Combined or Alternating Foscarnet/Ganciclovir Maintenance Therapy for AIDS Patients With CMV Retinitis After Ganciclovir Induction Therapy[NCT00000970] | Phase 1 | 30 participants | Interventional | Completed | |||
| Foscarnet Treatment of Serious CMV Retinitis Infection in Patients With Acquired Immunodeficiency Syndrome[NCT00000726] | Phase 1 | 53 participants | Interventional | Completed | |||
| Cytomegalovirus Retinitis Retreatment Trial[NCT00000134] | Phase 3 | 279 participants (Actual) | Interventional | 1992-12-31 | Completed | ||
| Foscarnet-Ganciclovir CMV Retinitis Trial[NCT00000136] | Phase 3 | 234 participants (Actual) | Interventional | 1990-03-31 | Completed | ||
| Studies of the Ocular Complications of AIDS (SOCA) CMV Retinitis Trial: Foscarnet-Ganciclovir Component[NCT00000665] | 240 participants | Interventional | Completed | ||||
| A Phase II Randomized Controlled Trial of Immediate Versus Delayed Foscarnet Therapy in AIDS Patients With Non-Immediately Sight-Threatening CMV Retinitis Who Cannot Be Treated With Ganciclovir Due to Myelosuppression[NCT00000697] | Phase 2 | 0 participants (Actual) | Interventional | Withdrawn | |||
| A Phase II Dose-Ranging, Open-Labelled Trial of Foscarnet Salvage Therapy for AIDS Patients With Sight-Threatening CMV Retinitis Who Cannot Be Treated With Ganciclovir Due To Myelosuppression or Treatment Failure[NCT00000691] | Phase 2 | 156 participants | Interventional | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
To determine the best therapeutic regimen, using currently approved drugs, for treatment of relapsed cytomegalovirus (CMV) retinitis. (NCT00000134)
Timeframe: Patients will be seen at baseline, monthly for six months, and then every three months until death or termination of the trial
| Intervention | participants (Number) |
|---|---|
| Intravenous Foscarnet | 88 |
| Intravenous Ganciclovir | 93 |
| Combination Therapy | 93 |
(NCT00000136)
Timeframe: All patients enrolled will be followed until a common study closing date, which was chosen to provide a minimum of 1 year of follow-up for all patients enrolled in the trial.
| Intervention | participants (Number) |
|---|---|
| Foscarnet | 107 |
| Ganciclovir | 127 |
18 reviews available for foscarnet and Retinitis
| Article | Year |
|---|---|
Retinal disease associated with AIDS.
Topics: AIDS-Related Opportunistic Infections; CD4-Positive T-Lymphocytes; Cytomegalovirus Infections; Eye I | 1993 |
Increased survival of a cohort of patients with acquired immunodeficiency syndrome and cytomegalovirus retinitis who received sodium phosphonoformate (foscarnet).
Topics: Acquired Immunodeficiency Syndrome; Cohort Studies; Cytomegalovirus Infections; Didanosine; Drug Tol | 1993 |
Ocular complications of the acquired immunodeficiency syndrome. Focus on the treatment of cytomegalovirus retinitis with ganciclovir and foscarnet.
Topics: Acquired Immunodeficiency Syndrome; Cytomegalovirus Infections; Eye Diseases; Foscarnet; Ganciclovir | 1993 |
New treatment options for CMV retinitis in AIDS.
Topics: AIDS-Related Opportunistic Infections; Antiviral Agents; Cytomegalovirus Retinitis; Drug Therapy, Co | 1997 |
Characteristics of cytomegalovirus retinitis in patients with acquired immunodeficiency syndrome.
Topics: Acquired Immunodeficiency Syndrome; Antiviral Agents; Cytomegalovirus Infections; Eye Infections, Vi | 1992 |
Maintenance therapy for cytomegalovirus retinitis in patients with acquired immunodeficiency syndrome: foscarnet.
Topics: Antiviral Agents; Cytomegalovirus Infections; Drug Therapy, Combination; Eye Infections, Viral; Fosc | 1992 |
Cytomegalovirus retinitis in AIDS.
Topics: Acquired Immunodeficiency Syndrome; Antiviral Agents; Cytomegalovirus Infections; Diagnosis, Differe | 1992 |
Foscarnet and ganciclovir in the treatment of cytomegalovirus retinitis.
Topics: Cytomegalovirus Infections; Drug Therapy, Combination; Foscarnet; Ganciclovir; Humans; Phosphonoacet | 1992 |
Foscarnet-induced penile ulcer.
Topics: Acquired Immunodeficiency Syndrome; Adult; Antiviral Agents; Cytomegalovirus Infections; Foscarnet; | 1992 |
Treatment and prophylaxis of cytomegalovirus disease.
Topics: Acquired Immunodeficiency Syndrome; Antiviral Agents; Cytomegalovirus Infections; Foscarnet; Gancicl | 1992 |
Foscarnet. A review of its antiviral activity, pharmacokinetic properties and therapeutic use in immunocompromised patients with cytomegalovirus retinitis.
Topics: Acquired Immunodeficiency Syndrome; Anemia; Animals; Antiviral Agents; Cytomegalovirus; Cytomegalovi | 1991 |
Approaches to the treatment of cytomegalovirus retinitis: ganciclovir and foscarnet.
Topics: Antiviral Agents; Cytomegalovirus Infections; Drug Therapy, Combination; Eye Infections, Viral; Fosc | 1991 |
Diagnosis and treatment of cytomegalovirus retinitis.
Topics: Antiviral Agents; Cytomegalovirus Infections; Diagnosis, Differential; Eye Infections, Viral; Foscar | 1991 |
Foscarnet sodium.
Topics: Acquired Immunodeficiency Syndrome; Antiviral Agents; Cytomegalovirus Infections; Eye Infections, Vi | 1991 |
Cotton-wool spots and cytomegalovirus retinitis in AIDS.
Topics: Acquired Immunodeficiency Syndrome; Acyclovir; Cytomegalovirus Infections; Diabetic Retinopathy; Dia | 1989 |
Cytomegalovirus infection in the acquired immune deficiency syndrome.
Topics: Acquired Immunodeficiency Syndrome; Acyclovir; Addison Disease; Antiviral Agents; Colitis; Cytomegal | 1989 |
Serious cytomegalovirus disease in the acquired immunodeficiency syndrome (AIDS). Clinical findings, diagnosis, and treatment.
Topics: Acquired Immunodeficiency Syndrome; Acyclovir; Antiviral Agents; Cytomegalovirus Infections; Foscarn | 1988 |
The diagnosis of cytomegalovirus retinitis.
Topics: Acquired Immunodeficiency Syndrome; Acyclovir; Antiviral Agents; Cytomegalovirus Infections; Diagnos | 1988 |
15 trials available for foscarnet and Retinitis
| Article | Year |
|---|---|
Dose-related difference in progression rates of cytomegalovirus retinopathy during foscarnet maintenance therapy. AIDS Clinical Trials Group Protocol 915 Team.
Topics: Acquired Immunodeficiency Syndrome; Adult; AIDS-Related Opportunistic Infections; Cytomegalovirus Re | 1995 |
Randomized phase I trial of two different combination foscarnet and ganciclovir chronic maintenance therapy regimens for AIDS patients with cytomegalovirus retinitis: AIDS clinical Trials Group Protocol 151.
Topics: Adolescent; Adult; AIDS-Related Opportunistic Infections; Cells, Cultured; Clinical Protocols; Cytom | 1994 |
Increased survival of a cohort of patients with acquired immunodeficiency syndrome and cytomegalovirus retinitis who received sodium phosphonoformate (foscarnet).
Topics: Acquired Immunodeficiency Syndrome; Cohort Studies; Cytomegalovirus Infections; Didanosine; Drug Tol | 1993 |
A dose-ranging study of daily maintenance intravenous foscarnet therapy for cytomegalovirus retinitis in AIDS.
Topics: Adolescent; Adult; Aged; AIDS-Related Opportunistic Infections; Cytomegalovirus Infections; Foscarne | 1993 |
Combination foscarnet and ganciclovir therapy vs monotherapy for the treatment of relapsed cytomegalovirus retinitis in patients with AIDS. The Cytomegalovirus Retreatment Trial. The Studies of Ocular Complications of AIDS Research Group in Collaboration
Topics: Adult; AIDS-Related Opportunistic Infections; Antiviral Agents; Cytomegalovirus Retinitis; Drug Ther | 1996 |
Cytomegalovirus (CMV) culture results, drug resistance, and clinical outcome in patients with AIDS and CMV retinitis treated with foscarnet or ganciclovir. Studies of Ocular Complications of AIDS (SOCA) in collaboration with the AIDS Clinical Trial Group.
Topics: AIDS-Related Opportunistic Infections; Antiviral Agents; Cytomegalovirus; Cytomegalovirus Infections | 1997 |
Foscarnet-Ganciclovir Cytomegalovirus Retinitis Trial: 5. Clinical features of cytomegalovirus retinitis at diagnosis. Studies of ocular complications of AIDS Research Group in collaboration with the AIDS Clinical Trials Group.
Topics: Acquired Immunodeficiency Syndrome; Adolescent; Adult; Antiviral Agents; Cytomegalovirus Infections; | 1997 |
The treatment of cytomegalovirus in AIDS--more than meets the eye.
Topics: Acquired Immunodeficiency Syndrome; Antiviral Agents; Cytomegalovirus Infections; Drug Therapy, Comb | 1992 |
Design of a randomized controlled trial of foscarnet in patients with cytomegalovirus retinitis associated with acquired immunodeficiency syndrome.
Topics: Acquired Immunodeficiency Syndrome; Adult; Antiviral Agents; Cytomegalovirus Infections; Eye Infecti | 1992 |
Studies of ocular complications of AIDS Foscarnet-Ganciclovir Cytomegalovirus Retinitis Trial: 1. Rationale, design, and methods. AIDS Clinical Trials Group (ACTG).
Topics: Acquired Immunodeficiency Syndrome; Antiviral Agents; Clinical Trials as Topic; Cytomegalovirus Infe | 1992 |
Studies of ocular complications of AIDS Foscarnet-Ganciclovir Cytomegalovirus Retinitis Trial: 1. Rationale, design, and methods. AIDS Clinical Trials Group (ACTG).
Topics: Acquired Immunodeficiency Syndrome; Antiviral Agents; Clinical Trials as Topic; Cytomegalovirus Infe | 1992 |
Studies of ocular complications of AIDS Foscarnet-Ganciclovir Cytomegalovirus Retinitis Trial: 1. Rationale, design, and methods. AIDS Clinical Trials Group (ACTG).
Topics: Acquired Immunodeficiency Syndrome; Antiviral Agents; Clinical Trials as Topic; Cytomegalovirus Infe | 1992 |
Studies of ocular complications of AIDS Foscarnet-Ganciclovir Cytomegalovirus Retinitis Trial: 1. Rationale, design, and methods. AIDS Clinical Trials Group (ACTG).
Topics: Acquired Immunodeficiency Syndrome; Antiviral Agents; Clinical Trials as Topic; Cytomegalovirus Infe | 1992 |
Effect of foscarnet therapy on human immunodeficiency virus p24 antigen levels in AIDS patients with cytomegalovirus retinitis.
Topics: Acquired Immunodeficiency Syndrome; Adult; Cytomegalovirus Infections; Dose-Response Relationship, D | 1992 |
Foscarnet and Ganciclovir in the treatment of CMV retinitis in AIDS patients: a randomised comparison.
Topics: Acquired Immunodeficiency Syndrome; Antiviral Agents; Cytomegalovirus Infections; Foscarnet; Gancicl | 1992 |
Mortality in patients with the acquired immunodeficiency syndrome treated with either foscarnet or ganciclovir for cytomegalovirus retinitis.
Topics: Acquired Immunodeficiency Syndrome; Adult; Antiviral Agents; CD4-Positive T-Lymphocytes; Cytomegalov | 1992 |
Mortality in patients with the acquired immunodeficiency syndrome treated with either foscarnet or ganciclovir for cytomegalovirus retinitis.
Topics: Acquired Immunodeficiency Syndrome; Adult; Antiviral Agents; CD4-Positive T-Lymphocytes; Cytomegalov | 1992 |
Mortality in patients with the acquired immunodeficiency syndrome treated with either foscarnet or ganciclovir for cytomegalovirus retinitis.
Topics: Acquired Immunodeficiency Syndrome; Adult; Antiviral Agents; CD4-Positive T-Lymphocytes; Cytomegalov | 1992 |
Mortality in patients with the acquired immunodeficiency syndrome treated with either foscarnet or ganciclovir for cytomegalovirus retinitis.
Topics: Acquired Immunodeficiency Syndrome; Adult; Antiviral Agents; CD4-Positive T-Lymphocytes; Cytomegalov | 1992 |
AIDS file.
Topics: Acquired Immunodeficiency Syndrome; Antiviral Agents; Cytomegalovirus Infections; Foscarnet; Gancicl | 1991 |
A randomized, controlled trial of foscarnet in the treatment of cytomegalovirus retinitis in patients with AIDS.
Topics: Acquired Immunodeficiency Syndrome; Adult; Antiviral Agents; Cytomegalovirus Infections; Eye Infecti | 1991 |
70 other studies available for foscarnet and Retinitis
| Article | Year |
|---|---|
Effects of intraocular treatments for Epstein-Barr virus (EBV) retinitis: A case report.
Topics: Adult; Epstein-Barr Virus Infections; Female; Foscarnet; Herpesvirus 4, Human; Humans; Methotrexate; | 2021 |
Intravitreal Foscarnet With Concurrent Silicone Oil Tamponade for Rhegmatogenous Retinal Detachment Secondary to Viral Retinitis.
Topics: Antiviral Agents; Combined Modality Therapy; Endotamponade; Eye Infections, Viral; Foscarnet; Humans | 2016 |
Cytomegalovirus encephalitis/retinitis in allogeneic haematopoietic stem cell transplant recipient treated successfully with combination of cidofovir and foscarnet.
Topics: Adolescent; Antiviral Agents; Cidofovir; Cytomegalovirus Infections; Cytosine; Encephalitis, Viral; | 2009 |
Successful treatment of varicella zoster virus retinitis with aggressive intravitreal and systemic antiviral therapy.
Topics: Acquired Immunodeficiency Syndrome; Adult; Antiviral Agents; Cidofovir; Cytosine; Drug Therapy, Comb | 2002 |
Successful treatment with combination of systemic antiviral drugs and intravitreal ganciclovir injections in the management of severe necrotizing herpetic retinitis.
Topics: Acyclovir; Adolescent; Adult; Antiviral Agents; Drug Therapy, Combination; Female; Foscarnet; Gancic | 2003 |
Intravitreal use of foscarnet: retinotoxicity of repeated injections in the rabbit eye.
Topics: Animals; Drug Administration Schedule; Electroretinography; Female; Foscarnet; Fundus Oculi; Male; O | 1994 |
Penile ulceration with foscarnet therapy.
Topics: AIDS-Related Opportunistic Infections; Cytomegalovirus Infections; Foscarnet; Humans; Male; Penile D | 1993 |
Foscarnet-induced severe hypomagnesemia and other electrolyte disorders.
Topics: Adult; Cytomegalovirus Infections; Foscarnet; HIV Infections; Hospitals, Community; Hospitals, Teach | 1993 |
Foscarnet--improving survival.
Topics: Cytomegalovirus Infections; Foscarnet; Humans; Retinitis | 1993 |
Intravitreal foscarnet for cytomegalovirus retinitis in a patient with acquired immunodeficiency syndrome.
Topics: AIDS-Related Opportunistic Infections; Cytomegalovirus Infections; Eye Infections, Viral; Foscarnet; | 1993 |
Foscarnet treatment in various cytomegalovirus infections.
Topics: Acquired Immunodeficiency Syndrome; Colitis; Cytomegalovirus Infections; Eye Infections, Viral; Fiss | 1993 |
Pathophysiology and treatment of clinically resistant cytomegalovirus retinitis.
Topics: Adult; AIDS-Related Opportunistic Infections; Cytomegalovirus; Cytomegalovirus Infections; Drug Resi | 1993 |
Treatment of cytomegalovirus retinitis in patients with AIDS.
Topics: AIDS-Related Opportunistic Infections; Antiviral Agents; Cidofovir; Cytomegalovirus Infections; Cyto | 1996 |
Repair of retinal detachments due to herpes varicella-zoster virus retinitis in patients with acquired immune deficiency syndrome.
Topics: Adult; AIDS-Related Opportunistic Infections; Antiviral Agents; Foscarnet; Ganciclovir; Herpes Zoste | 1997 |
New therapies for cytomegalovirus retinitis in patients with the acquired immunodeficiency syndrome.
Topics: AIDS-Related Opportunistic Infections; Antiviral Agents; Cidofovir; Cytomegalovirus Infections; Cyto | 1997 |
Management of varicella zoster virus retinitis in AIDS.
Topics: Acquired Immunodeficiency Syndrome; Acyclovir; Adult; AIDS-Related Opportunistic Infections; Analysi | 1997 |
Concurrent ganciclovir and foscarnet treatment for cytomegalovirus encephalitis and retinitis in an infant with acquired immunodeficiency syndrome: case report and review.
Topics: AIDS-Related Opportunistic Infections; Antiviral Agents; Cytomegalovirus Infections; Drug Therapy, C | 1997 |
Varicella zoster virus retrobulbar optic neuritis preceding retinitis in patients with acquired immune deficiency syndrome.
Topics: Acyclovir; Adult; AIDS-Related Opportunistic Infections; Antiviral Agents; Cerebrospinal Fluid; Fema | 1998 |
Guidelines for the treatment of cytomegalovirus diseases in patients with AIDS in the era of potent antiretroviral therapy: recommendations of an international panel. International AIDS Society-USA.
Topics: AIDS-Related Opportunistic Infections; Anti-HIV Agents; Antiviral Agents; Cidofovir; Cytomegalovirus | 1998 |
Treatment of herpes retinitis in an animal model with a sustained delivery antiviral drug, liposomal 1-O-octadecyl-SN-glycerol-3-phosphonoformate.
Topics: Animals; Antiviral Agents; Delayed-Action Preparations; Disease Models, Animal; Drug Carriers; Eye I | 1999 |
Intravitreal toxicology and therapeutic efficacy of the carboxymethyl ester of the 1-O-octadecyl-sn-glycerol-3-phosphonoformate (ODG-PFA-O-Me), a novel lipid antiviral prodrug for intraocular drug delivery.
Topics: Animals; Antiviral Agents; Cytomegalovirus Infections; Electroretinography; Fluorescein Angiography; | 1999 |
Reducing chorioretinal viral counts with intravitreal foscarnet injections in a rabbit model of Herpes simplex virus type-1 retinitis.
Topics: Administration, Topical; Animals; Choroid; Foscarnet; Herpes Simplex; Herpesvirus 1, Human; Ophthalm | 1999 |
From the National Institutes of Health.
Topics: Acquired Immunodeficiency Syndrome; Anti-Inflammatory Agents, Non-Steroidal; Antiviral Agents; Arthr | 1992 |
Foscarnet.
Topics: Acquired Immunodeficiency Syndrome; Antiviral Agents; Cytomegalovirus Infections; Eye Infections, Vi | 1992 |
Didanosine and foscarnet marketed for use by patients with AIDS.
Topics: Acquired Immunodeficiency Syndrome; Antiviral Agents; Cytomegalovirus Infections; Didanosine; Foscar | 1992 |
Clinical implications of herpesvirus infections in patients with AIDS. Introduction.
Topics: Acquired Immunodeficiency Syndrome; Antiviral Agents; Cytomegalovirus Infections; Eye Infections, Vi | 1992 |
Treatment of cytomegalovirus retinitis--1992.
Topics: Acquired Immunodeficiency Syndrome; Antiviral Agents; Cytomegalovirus Infections; Eye Infections, Vi | 1992 |
Treatment of aggressive cytomegalovirus retinitis with ganciclovir in combination with foscarnet in a child infected with human immunodeficiency virus.
Topics: Antiviral Agents; Child, Preschool; Cytomegalovirus Infections; Drug Therapy, Combination; Female; F | 1992 |
Why was treatment of cytomegalovirus retinitis randomized?
Topics: Antiviral Agents; Cytomegalovirus Infections; Eye Infections, Viral; Foscarnet; Ganciclovir; Humans; | 1992 |
Cytomegalovirus and AIDS.
Topics: Acquired Immunodeficiency Syndrome; Adult; Antiviral Agents; Cytomegalovirus Infections; Foscarnet; | 1992 |
Treatment of CMV retinitis.
Topics: Acquired Immunodeficiency Syndrome; Antiviral Agents; Cytomegalovirus Infections; Drug Therapy, Comb | 1992 |
Treatment of CMV retinitis.
Topics: Acquired Immunodeficiency Syndrome; Antiviral Agents; Cytomegalovirus Infections; Foscarnet; Gancicl | 1992 |
Treatment of CMV retinitis.
Topics: Acquired Immunodeficiency Syndrome; Antiviral Agents; Cytomegalovirus Infections; Foscarnet; Gancicl | 1992 |
Foscarnet induction therapy for cytomegalovirus retinitis in AIDS: comparison of twice-daily and three-times-daily regimens.
Topics: Acquired Immunodeficiency Syndrome; Adult; Antiviral Agents; Cytomegalovirus Infections; Drug Admini | 1992 |
Therapeutic algorithm for treatment of cytomegalovirus retinitis in persons with AIDS. A roundtable summary.
Topics: Acquired Immunodeficiency Syndrome; Adult; Algorithms; Cytomegalovirus Infections; Foscarnet; Gancic | 1992 |
Herpes simplex virus infection during foscarnet therapy.
Topics: Acquired Immunodeficiency Syndrome; Adult; Antiviral Agents; Cytomegalovirus Infections; Foscarnet; | 1992 |
Atypical healing of cytomegalovirus retinitis. Significance of persistent border opacification.
Topics: AIDS-Related Opportunistic Infections; Antiviral Agents; Cytomegalovirus; Cytomegalovirus Infections | 1992 |
Visual field testing in the management of cytomegalovirus retinitis.
Topics: Adult; AIDS-Related Opportunistic Infections; Antiviral Agents; Cytomegalovirus Infections; Eye Infe | 1992 |
Intravitreal foscarnet for cytomegalovirus retinitis in a patient with acquired immunodeficiency syndrome.
Topics: Acquired Immunodeficiency Syndrome; Adult; Cytomegalovirus Infections; Eye Infections, Viral; Follow | 1992 |
When you give foscarnet to patients at home.
Topics: AIDS-Related Opportunistic Infections; Community Health Nursing; Cytomegalovirus Infections; Foscarn | 1992 |
Foscarnet-induced hypokalaemia.
Topics: Cytomegalovirus Infections; Female; Foscarnet; HIV Seropositivity; HIV-1; Humans; Hypokalemia; Male; | 1992 |
2.5 years survival with sequential ganciclovir/foscarnet treatment in a patient with acquired immune deficiency syndrome and cytomegalovirus retinitis.
Topics: AIDS-Related Opportunistic Infections; Cataract Extraction; Cytomegalovirus Infections; Drug Adminis | 1992 |
Opportunistic intraocular infections in AIDS.
Topics: Adolescent; Adult; AIDS-Related Opportunistic Infections; Child; Child, Preschool; Choroiditis; Cyto | 1992 |
[Cytomegalovirus retinitis in AIDS. Effectiveness and complications of long-term therapy].
Topics: AIDS-Related Opportunistic Infections; Cytomegalovirus Infections; Foscarnet; Ganciclovir; Humans; L | 1992 |
Treatment of CMV retinitis.
Topics: Acquired Immunodeficiency Syndrome; Antiviral Agents; Cytomegalovirus Infections; Eye Infections, Vi | 1992 |
Foscarnet for CMV retinitis.
Topics: Acquired Immunodeficiency Syndrome; Antiviral Agents; Cytomegalovirus Infections; Foscarnet; Gancicl | 1992 |
Foscarnet therapy for ganciclovir-resistant cytomegalovirus retinitis in patients with AIDS.
Topics: Acquired Immunodeficiency Syndrome; Adult; Antiviral Agents; Cytomegalovirus; Cytomegalovirus Infect | 1991 |
Successful foscarnet therapy for cytomegalovirus retinitis in an AIDS patient undergoing hemodialysis: rationale for empiric dosing and plasma level monitoring.
Topics: Acquired Immunodeficiency Syndrome; Acute Kidney Injury; Adult; Antiviral Agents; Cytomegalovirus In | 1991 |
National Eye Institute issues clinical alert about CMV retinitis in AIDS.
Topics: Acquired Immunodeficiency Syndrome; Antiviral Agents; Cytomegalovirus Infections; Eye Infections, Vi | 1991 |
Foscarnet approved for cytomegalovirus retinitis.
Topics: Acquired Immunodeficiency Syndrome; Antiviral Agents; Cytomegalovirus Infections; Foscarnet; Humans; | 1991 |
From the Food and Drug Administration.
Topics: Acquired Immunodeficiency Syndrome; Antiviral Agents; Cytomegalovirus Infections; Eye Infections, Vi | 1991 |
Cytomegalovirus infection in AIDS. Patterns of disease, response to therapy and trends in survival.
Topics: Acquired Immunodeficiency Syndrome; Antiviral Agents; Colitis; Cytomegalovirus Infections; Female; F | 1991 |
Survival of patients with AIDS and cytomegalovirus disease treated with ganciclovir or foscarnet.
Topics: Acquired Immunodeficiency Syndrome; Adult; Antiviral Agents; Cytomegalovirus Infections; Female; Fos | 1991 |
Early virus isolation, early structural antigen detection and DNA amplification by the polymerase chain reaction in polymorphonuclear leukocytes from AIDS patients with human cytomegalovirus viraemia.
Topics: Acquired Immunodeficiency Syndrome; Antigens, Viral; Antiviral Agents; Cytomegalovirus; Cytomegalovi | 1991 |
Simultaneous treatment of cytomegalovirus retinitis with ganciclovir and foscarnet.
Topics: Acquired Immunodeficiency Syndrome; Adult; Antiviral Agents; Cytomegalovirus Infections; Eye Infecti | 1991 |
Treatment of cytomegalovirus retinitis with ganciclovir and foscarnet.
Topics: Adult; Cytomegalovirus Infections; Drug Combinations; Foscarnet; Ganciclovir; HIV Seropositivity; Hu | 1991 |
Seeing the way forward for treatment of CMV retinitis.
Topics: Acquired Immunodeficiency Syndrome; Antiviral Agents; Clinical Trials as Topic; Cytomegalovirus Infe | 1991 |
CMV retinitis and the use of FK 506.
Topics: Acyclovir; Antiviral Agents; Cytomegalovirus Infections; Foscarnet; Humans; Immunosuppression Therap | 1991 |
Foscarnet therapy of cytomegalovirus retinitis in AIDS.
Topics: Acquired Immunodeficiency Syndrome; Antiviral Agents; Cytomegalovirus Infections; Foscarnet; Humans; | 1990 |
Nephrogenic diabetes insipidus associated with foscarnet treatment of cytomegalovirus retinitis.
Topics: Acquired Immunodeficiency Syndrome; Adult; Antiviral Agents; Cytomegalovirus Infections; Diabetes In | 1990 |
Foscarnet in the treatment of cytomegalovirus retinitis in acquired immune deficiency syndrome.
Topics: Acquired Immunodeficiency Syndrome; Adult; Creatine; Cytomegalovirus Infections; Drug Therapy, Combi | 1989 |
Foscarnet treatment of cytomegalovirus retinitis in patients with the acquired immunodeficiency syndrome.
Topics: Acquired Immunodeficiency Syndrome; Adult; Antiviral Agents; Calcium; Cytomegalovirus Infections; Fo | 1989 |
Pharmacokinetics of intermittently administered intravenous foscarnet in the treatment of acquired immunodeficiency syndrome patients with serious cytomegalovirus retinitis.
Topics: Acquired Immunodeficiency Syndrome; Adult; Antiviral Agents; Cytomegalovirus Infections; Foscarnet; | 1989 |
Foscarnet infusion at home.
Topics: Acquired Immunodeficiency Syndrome; Adult; Antiviral Agents; Cytomegalovirus Infections; Drug Admini | 1989 |
Treatment of CMV retinitis in an AIDS patient.
Topics: Acquired Immunodeficiency Syndrome; Acyclovir; Antiviral Agents; Cytomegalovirus Infections; Foscarn | 1987 |
Treatment of cytomegalovirus retinitis with trisodium phosphonoformate hexahydrate (Foscarnet).
Topics: Acquired Immunodeficiency Syndrome; Adult; Antiviral Agents; Cytomegalovirus Infections; Foscarnet; | 1988 |
Effect of Foscarnet therapy on infection with human immunodeficiency virus in patients with AIDS.
Topics: Acquired Immunodeficiency Syndrome; Antiviral Agents; Cytomegalovirus Infections; Foscarnet; HIV; HI | 1988 |
Foscarnet as treatment for cytomegalovirus retinitis following bone marrow transplantation.
Topics: Adult; Antiviral Agents; Bone Marrow Transplantation; Busulfan; Cataract; Cytomegalovirus Infections | 1988 |
Foscarnet infusion at home.
Topics: Acquired Immunodeficiency Syndrome; Adult; Cytomegalovirus Infections; Foscarnet; HIV Antigens; Home | 1988 |
Foscarnet for cytomegalovirus retinitis.
Topics: Acquired Immunodeficiency Syndrome; Antiviral Agents; Cytomegalovirus Infections; Foscarnet; Humans; | 1985 |